Anand Padmanabhan, M.B.B.S., Ph.D., has translational research interests in the area of platelet immunology with a focus on heparin-induced thrombocytopenia. He also has clinical and research interests in the use of apheresis therapies in human disease and collection of cellular blood components for novel cell therapies.
Heparin-induced thrombocytopenia causes more than five deaths each day in the United States. Timely and accurate diagnosis is a challenge. Current testing algorithms frequently lead to overdiagnosis of the condition in some instances and delayed diagnosis in others. Dr. Padmanabhan's research seeks to significantly change the testing paradigm so that early and accurate diagnosis of heparin-induced thrombocytopenia can facilitate timely, appropriate therapy.
His interests in transfusion medicine and cellular therapies include apheresis collections and treatments and platelet transfusion refractoriness. Evidence-based use of apheresis, hematologic cell collections and optimization of vascular access to facilitate apheresis are particular areas of focus.
Dr. Padmanabhan's research includes:
- Epidemiology — Clarifying heparin-induced thrombocytopenia incidence in various patient populations
- Pathophysiology — Investigating the biochemical basis of the difference between pathogenic and benign heparin-induced thrombocytopenia antibodies
- Diagnosis — Developing novel technologies and processes to facilitate early and accurate diagnosis of heparin-induced thrombocytopenia
- Treatment — Investigating new treatments for heparin-induced thrombocytopenia, especially for patients with severe presentations
Significance to patient care
Dr. Padmanabhan's research has led to better ways of diagnosing heparin-induced thrombocytopenia, a disorder in which early diagnosis is critical for appropriate management. His research has also provided new ways to manage severe heparin-induced thrombocytopenia that is resistant to standard therapies. A better understanding of heparin-induced thrombocytopenia pathophysiology is important in making further improvements in prevention, diagnosis and treatment.
Dr. Padmanabhan led the evidence-based writing group of the American Society for Apheresis that discusses the use of apheresis in numerous disease states. This is of relevance to patients with many organ system diseases and disorders amenable to apheresis therapies.
- Member, Scientific Committee on Thrombosis and Vascular Biology, American Society of Hematology, 2020-2023
- Editor, Journal of Clinical Apheresis, 2017-present
- Member and American Society for Apheresis representative, Committee on Practice, American Society of Hematology, 2017-present
- Recipient, Lecturer Award, American Society for Apheresis, 2018
- Recipient, National Blood Foundation Award for Innovative Research, 2016